What Looks Like Acrocyanosis?
Discussion
Acrocyanosis is a peripheral vascular disease where the skin and mucous membranes have a persistent, painless, deep-bluish color due to decreased oxygenated blood which usually is benign. The deoxygenated blood can be due to a central cause such as cyanotic congenital heart disease or localized problems often due to vasospasm. Hands and feet are the most common areas affected. It is thought that there is “…vasospasm of the cutaneous arteries, and arterioles along with compensatory dilatation in the capillary and post capillary venules caus[ing] cyanosis and sweating.” Palms and soles may or may...
Source: PediatricEducation.org - September 27, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
KJ Apa Is a Dad! Riverdale Star and Model Clara Berry Welcome First Baby
"I am the luckiest to have now two men of my life, filling my heart with this cosmic gigantic vast love," Berry wrote announcing the... (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2021 Category: Consumer Health News Source Type: news
Breastfeeding May Strengthen a Baby's Heart
This study … adds to the already known benefits of breast milk for infants born prematurely, " said study leader Dr. Afif El-Khuffash, a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2021 Category: General Medicine Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
When Will COVID-19 Vaccines Be Available for Younger Kids?
As the school year gets underway and the Delta variant continues its march through the U.S. population, many parents with kids younger than 12 have the same question: When will vaccines become available for my child?
No one knows exactly when the U.S. Food and Drug Administration (FDA) may grant one or multiple COVID-19 vaccines emergency-use authorization for children younger than 12. But Dr. Robert Frenck, director of the Vaccine Research Center at Cincinnati Children’s Hospital Medical Center and one of the investigators involved in testing Pfizer-BioNTech’s shot in kids, guesses parents will have to wait at...
Source: TIME: Health - August 30, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Slain Marine who cradled baby at Kabul airport loved her job
Heart-wrenching details have emerged about some of the 13 U.S. troops killed in a horrific suicide bombing at Afghanistan’s Kabul... (Source: Reuters: Health)
Source: Reuters: Health - August 28, 2021 Category: Consumer Health News Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
AHA News: Son's Scary Heart Defect Led Couple to Help Other Parents
TUESDAY, Aug. 17, 2021 (American Heart Association News) -- Linda and Clint Pilkinton had a healthy toddler when Linda got pregnant with their second child. They were eager to give Charlie a baby brother.
The first trimester of her pregnancy... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 17, 2021 Category: General Medicine Source Type: news
DR Congo, Ituri. Fleeing War, Weaving Life in IDP Camps of Bunia
The man reading is a displaced man in the IDP camp ISP in Bunia. Credit: Elena L. Pasquini By Elena L. PasquiniROME, Jul 29 2021 (IPS) He moves aside the curtain, thin as gauze, and then bends over. The darkness dazzles for a few seconds when one enters the house—actually, a den made of earth where air and light filter through the narrow entrance. Jean de Dieu Amani Paye holds her tiny baby, wrapped in an elegant fabric, in his arms. He was a teacher of French and Latin and had a small business. He also cultivated the land: cassava, corn, sorghum, and beans.
Now he is a leader of the ISP camp on the outskirts of Bunia, ...
Source: IPS Inter Press Service - Health - July 29, 2021 Category: International Medicine & Public Health Authors: Elena Pasquini Tags: Africa Aid Armed Conflicts Crime & Justice Featured Gender Violence Headlines Health Human Rights Humanitarian Emergencies Migration & Refugees TerraViva United Nations Women's Health Source Type: news
AHA News: She Had a Baby. Then Emergency Heart Surgery. And a Stroke. Then, a New Heart.
THURSDAY, July 29, 2021 (American Heart Association News) -- In her third trimester, Kristy Novillo struggled to give tours of the Redmond, Washington, child care center where she worked as a director. Walking and talking at the same time left her... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 29, 2021 Category: General Medicine Source Type: news
Shortages Reveal Low Priority of Women ’s Health in Nepal
Chiring Tamang holds the family’s new baby while his wife Priya looks on. She delivered the girl at home in their village in Nepal’s Sindhupalchowk district in February 2021. Credit: Marty Logan / IPSBy Marty LoganKathmandu, Nepal, Jul 21 2021 (IPS) One year after Nepal’s Ministry of Health (MoH) appealed to international organisations in the country to urgently supply a drug used to stop excessive bleeding after childbirth, a UN agency has delivered $1 million worth of contraceptives to prevent another shortage.
The 1.6 million cycles of oral contraceptive pills and 776,000 units of injectable contraceptives and sy...
Source: IPS Inter Press Service - Health - July 21, 2021 Category: International Medicine & Public Health Authors: Marty Logan Tags: Asia-Pacific COVID-19 Featured Gender Headlines Health Human Rights Humanitarian Emergencies Inequity TerraViva United Nations Women's Health contraceptives UNFPA United Nations Population Fund (UNFPA) Source Type: news
AHA News: Pregnant Mom's Diet May Influence Baby's Cardiovascular Health
MONDAY, July 19, 2021 (American Heart Association News) -- A pregnant woman ' s diet and other lifestyle factors may change how her baby ' s genes work in a way that can affect the child ' s cardiovascular health by age 8 or 9, new research has... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 19, 2021 Category: General Medicine Source Type: news
Hope, horror and Covid-19: my 23 years as the Guardian ’s health correspondent | Sarah Boseley
I ’ve travelled the world covering everything from HIV to MMR to Ebola… and then Covid came along. These are stories that changed me – and the worldShe was tall, wrapped in a green patterned dress that clung to her legs and ended just above dusty flip-flops. In the bustling, sweltering market, Grace Mathanga looked at me appraisingly, as if to say: “What have we here?” And I knew she was the one.It was the end of2002. I had flown to Lilongwe, the capital of Malawi, with excitement in my heart and fear of failure eating at my gut. I ’d been the Guardian’s health correspondent for a couple of years, and had wri...
Source: Guardian Unlimited Science - July 17, 2021 Category: Science Authors: Sarah Boseley Tags: Health Coronavirus Aids and HIV Infectious diseases Vaccines and immunisation Society Ebola Africa Epidemics World news Global health Global development Campaigning journalism Newspapers & magazines Media Source Type: news
New research aims to improve treatments and outcomes for people with severe asthma
(Cleveland Clinic) A new phase 2 clinical trial of multiple therapies for severe asthma is underway in Northeast Ohio, with a focus on personalized therapies based on genetics, family history, lifestyle and environmental factors.The Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) study, sponsored by the National Heart, Lung and Blood Institute (NHBLI), is enrolling patients at Cleveland Clinic and University Hospitals Rainbow Babies& Children's Hospital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2021 Category: International Medicine & Public Health Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
